Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
Terminated
Windtree Therapeutics
Phase 3
2000-03-01
OBJECTIVES:
Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL)
in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
Terminated
Windtree Therapeutics
Phase 2
2005-02-01
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to
prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia
(BPD), in premature infants who have required continued intubation and received surfactants
for the prevention or treatment of respiratory distress syndrome (RDS).
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to
usual care alone consisting primarily of assisted (mechanical) ventilation in patients with
acute respiratory distress syndrome(ARDS).
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
Completed
Windtree Therapeutics
Phase 2
2007-06-01
Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated
in young children with acute respiratory failure who require mechanical ventilation (life
support), to determine if it is safe and if treatment with lucinactant will reduce the number
of days a child needs mechanical ventilation (life support).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
